PolyGene is a strong biotech partner in EU projects.
We are an active contributor to research and development within the European Union frameworks
- to push forward PolyGene’s in-house research and innovation endeavours
- to establish new state-of-the-art technologies
- to generate new products for the biotechnology and pharmaceutical industry (e.g. animal models of human disease)
PolyGene is a leading partner in the following EU projects:
Identification and validation of novel pharmaceutical drug targets for cardiovascular disease (since 2013)
Cardiovascular disease (CVD), including high blood pressure, coronary artery disease, heart disease and stroke, is the leading cause of death in the world. To improve the life-expectancy of CVD patients, the multi-partner, FP7-funded consortium CarTarDis (Cardiovascular Target Discovery) set out to advance the ...» read more